Related Experiment Video
Updated: Nov 4, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?
A Mohammed Idhrees1, Prasanna Karthik Suthakaran2, George Jose Valooran3
1Institute of Cardiac and Aortic Disorders, SRM Institutes for Medical Science (SIMS Hospital), Chennai, Tamil Nadu, India.
Abstract:
Infection with the novel coronavirus, SARS-CoV2, produces the clinical syndrome COVID-19. COVID-19 is a systemic illness inducing hyperinflammation and cytokine storm affecting multiple organs including the myocardium which is reflected in elevated cardiac biomarkers such as troponin, lactate dehydrogenase, and creatinine kinase MB. Furthermore, COVID-19 has been implicated in increased predilection to thromboembolic phenomena. Hence, mortality in patients with associated cardiovascular disease has been higher compared with the cohort with no cardiovascular comorbidity. It is entirely unknown how remdesivir will change the facet of cardiovascular medicine and surgery. In the present constantly changing climate, this review of remdesivir and its association with cardiovascular disease is comprehensive as of June 17, 2020 and it highlights the science behind this drug and its potential implications to cardiovascular practice.
Related Concept Videos
Myocarditis III: Medical Management
Cardiopulmonary Resuscitation IV: Pharmacological Management
Rheumatic Heart Disease III: Medical Management
Cardiovascular Drugs: Classification based on Therapeutic Indications
Endocarditis III: Medical Management
Coronary Artery Disease IV: Preventive Measures

